This paper describes recent efforts on the use of Reversible Addition-Fragmentation Chain Transfer (RAFT) polymerization for synthesis of well-defined polymer conjugates for delivery of bioactives. The research is illustrated by work on with the antitumor drug SN38, to improve water solubility and cell viability, and the delivery of siRNA, for gene silencing. The RAFT polymers are conjugated to the active through a covalent linkage, in the case of anticancer drug SN38, and by ionic association, for the case of siRNA. Preliminary results are extremely encouraging. The synthesized RAFT ABA triblock polymers provided 100% siRNA uptake and gave gene silencing similar to that of the transfection reagent Lipofectamine™. In both examples RAFT-acive conjugates polymers were well-tolerated showing no discernable cell cytotoxicity.
|Title of host publication||Technical Proceedings of the 2011 NSTI Nanotechnology Conference and Expo, NSTI-Nanotech 2011|
|Subtitle of host publication||Boston, MA, United States; 13-16 June 2011|
|Number of pages||3|
|Publication status||Published - 23 Nov 2011|
- RAFT polymerization
- SN38 antitumor drug